The Weekly Roundup newsletter curates the top five - deals, pipeline, funding, and news from the past week.

The complete list is available here: Industry Updates

🤝Deals and Collaborations

1️⃣ Lilly acquires Dice Therapeutics for $2.4B, targeting IL-17 with lead candidate DC-806 in phase 2 trials for psoriasis. //Read more

2️⃣ Bio-Techne acquires Lunaphore, advancing scientific discovery and therapeutic development in immunology, immuno-oncology, and neuroscience. //Read more

3️⃣ Prime Medicine and Cimeio Therapeutics collaborate to develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for genetic diseases and blood disorders, leveraging Prime Editing and SCIP platforms. //Read more

4️⃣ Aslan sells Japanese rights for potential Dupixent rival, eblasakimab, to Zenyaku for $12M to develop and commercialize in atopic dermatitis and other indications. //Read more

5️⃣ Talaris Therapeutics and Tourmaline Bio merge to form a Nasdaq-listed, late-stage biotech company developing anti-IL-6 antibody TOUR006 for thyroid eye disease and cardiovascular disease. //Read more

⏫ Pipeline and Approvals

1️⃣ Genetic disorder: FDA approves Argenx's Vyvgart Hytrulo, an under-the-skin injection for treating muscle-weakening genetic disease generalized myasthenia gravis, with availability in the US next month. //Explore further

2️⃣ Diabetes: FDA approves Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin hydrochloride) as new oral medicines to improve blood sugar control in children aged 10 years and older with type 2 diabetes, providing an important addition to the limited treatment options currently available for pediatric patients. //Explore further

3️⃣ Vaccine: Gennova Biopharmaceuticals' Gemcovac-OM, India's first mRNA Covid-19 booster vaccine against the Omicron variant, receives emergency use authorization from DCGI. //Explore further

4️⃣ Cardiology: Agepha Pharma's Lodoco, a colchicine-based formulation, receives FDA approval as the first drug to treat vascular inflammation in heart disease patients. //Explore further

5️⃣ Oncology: Amgen receives US FDA full approval for Blincyto to treat minimal residual disease-positive B-cell precursor acute lymphoblastic leukemia in adults and pediatric patients. //Explore further

💰 Funding

1️⃣ Startup Tagworks raises $65M to advance 'click-to-release' cancer drugs, focusing on lead ADC candidate TGW101 targeting TAG72 in various tumor types. //Learn more

2️⃣ WestGene Biopharma secures $42M in Series A funding to advance mRNA portfolio, including trials for EBV-positive tumor and liver cancer mRNA therapeutic vaccines. //Learn more

3️⃣ Attovia Therapeutics launches with $60M Series A funding to advance its nanobody platform and clinical proof-of-concept for immune-mediated diseases in immunology and oncology. //Learn more

4️⃣ Artbio launches to develop Alpha Radioligand Therapies, with funding supporting clinical development of lead program AB001 for prostate cancer and advancement of AlphaDirect™ Pb212 isolation technology. //Learn more

5️⃣ AltPep raises $52.9M Series B to accelerate Phase 1 clinical trials for AltPep’s SOBIN™ therapeutics in Alzheimer's and Parkinson's diseases and advance FDA-cleared SOBA™ diagnostic. //Learn more

📰 Interesting News

1️⃣ Researchers discover hidden mechanism linking insulin resistance to cancer, causing faster cancer spread in patients. //Find out more

2️⃣ Five osteoporosis research advancements: new oral treatment, estrogen delivery for fracture healing, key driver of low bone density, positive phase 1 trial results, and predictive model for drug combinations. //Find out more

3️⃣ Next-gen startups emerge in cell and gene therapy manufacturing as over 2,200 global clinical trials strain the capacity of large contract manufacturers, causing lengthy waitlists. //Find out more

4️⃣ Global diabetes cases are predicted to exceed one billion by 2050, defining health and life expectancy for the century as the world grapples with the disease's social nature and underestimated threat. //Find out more

5️⃣ Wearable monitor offers blood-free, 24-hour stress hormone detection, improving accuracy in detecting early signs of endocrine diseases compared to single-point tests. //Find out more